n-Butyl-2-[4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-imidazole-2-yl] isobutylamide | 359889-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: n-Butyl-2-[4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-imidazole-2-yl] isobutylamide
• 英文别名: N-butyl-2-[4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-2-methylpropanamide
• CAS: 359889-14-8
• 化学式: C₂₃H₂₇ClN₄O₂
• 分子量: 426.946
• InChiKey: ZFABFTYPBTUFQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  n-Butyl-2-[4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-imidazole-2-yl] isobutylamide 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以82%的产率得到n-Butyl-2-[4-(4-chloro-3-hydroxyphenyl)-5-pyridin-4-yl-1H-imidazole-2-yl]isobutylamide
  参考文献：
  名称：

  US2003/153588

  摘要：

  公开号：

文献信息

• Imidazol derivatives as raf kinase inhibitors
  申请人：——

  公开号：US20030153588A1

  公开（公告）日：2003-08-14

  Compounds of formula (I) wherein X is O, CH 2 , S or NH, or the moiety X—R 1 is hydrogen; V is CH or N; R 1 is hydrogen, C 1-6 -alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heterocyclyl, heterocyclylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl any of which except for hydrogen may be optionally substituted; R 2 and R 3 independently represent optionally substituted C 1-6 -alkyl, or R 2 and R 3 together with the carbon atom to which they are attached form an optionally substituted C 3-7 cycloalkyl or C 3-7 cycloalkenyl ring; or R 2 and R 3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R 4 and R 5 independently represent hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heteroaryl, heteroarylC 1-6 alkyl, heterocyclyl, or heterocyclylC 1-6 alkyl, any of which except for hydrogen may be optionally substituted or R 4 and R 5 together with the nitrogen atom to which they are attached form 4- to 8-membered ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X 1 and X 2 is N and the other is NR 6 , wherein R 6 is hydrogen, C 1-6 alkyl, or arylC 1-6 alkyl or pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them.
• Imidazol derivatives as Raf kinase inhibitors
  申请人：Steadman Graham Jon

  公开号：US20060122207A1

  公开（公告）日：2006-06-08

  Compounds of formula (I): wherein X is O, CH 2 , S or NH, or the moiety X—R 1 is hydrogen; V is CH or N; R 1 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heterocyclyl, heterocyclylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl any of which except for hydrogen may be optionally substituted; R 2 and R 3 independently represent optionally substituted C 1-6 alkyl, or R 2 and R 3 together with the carbon atom to which they are attached form an optionally substituted C 3-7 cycloalkyl or C 3-7 cycloalkenyl ring; or R 2 and R 3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R 4 and R 5 independently represent hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heteroaryl, heteroarylC 1-6 alkyl, heterocyclyl, or heterocyclylC 1-6 alkyl, any of which except for hydrogen may be optionally substituted or R 4 and R 5 together with the nitrogen atom to which they are attached form 4- to 8-membered ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X 1 and X 2 is N and the other is NR 6 , wherein R 6 is hydrogen, C 1-6 alkyl, or arylC 1-6 alkyl or pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them.
• US7235658B2
  申请人：——

  公开号：US7235658B2

  公开（公告）日：2007-06-26